Will require pharmacy benefit managers to pass through all insulin rebates and manufacturer discounts to plan sponsors.

Mandates pharmacy benefit managers (PBMs) pass through 100% of insulin rebates and other discounts received from manufacturers to plan sponsors, reducing perverse incentives in the insulin market that encourage high list prices and help patients in the form of reduced premiums.

Shaheen's INSULIN Act would require PBMs to pass through 100% of insulin rebates and other manufacturer discounts to plan sponsors.

ICYMI: Shaheen Details Efforts to Make Insulin Affordable on A Starting Point
primary · interview · model gpt-5.5

Fourteen Senators from each party now cosponsor the Shaheen-led bill to lower insulin costs for Americans with and without insurance.

Shaheen's announcement concerns the INSULIN Act, which includes insulin-market reforms including PBM rebate and discount pass-through requirements.

Shaheen Announces 2 New Cosponsors of Bipartisan Bill to Cap Monthly Insulin Costs at $35, Bringing Total to 28 Bipartisan Senators
primary · press_release · model gpt-5.5

Section 6702 is titled Full Rebate Pass Through to Plan. It requires pharmacy benefit management service contracts to remit 100 percent of rebates, fees, alternative discounts, and other remuneration related to drug utilization or spending to the group health plan or issuer acting on behalf of the plan.

The enacted 2026 appropriations law contains a broad PBM rebate pass-through requirement for group health plans. Because it applies to drug utilization generally, it includes insulin rebates and manufacturer discounts within covered plans.

delivered same_term A for effort

Congress.gov bill text for H.R.7148, Consolidated Appropriations Act, 2026
secondary · model gpt-5.5 · confidence 90%

Congress.gov lists H.R.7148 as a law and records that it passed the Senate on January 30, 2026, passed final House resolving action on February 3, 2026, and became Public Law No. 119-75 on February 3, 2026.

The PBM pass-through language was not merely proposed; it was enacted as part of Public Law 119-75 during Shaheen's 2021-2027 Senate term.

delivered same_term A for effort

Congress.gov actions for H.R.7148, Consolidated Appropriations Act, 2026
secondary · model gpt-5.5 · confidence 92%

The Senate roll call for H.R.7148 as amended shows the bill passed 71-29 on January 30, 2026, and lists Shaheen (D-NH) as voting Yea.

Shaheen voted for final Senate passage of the bill that included the PBM rebate pass-through provisions.

delivered same_term A for effort

U.S. Senate Roll Call Vote 119th Congress, 2nd Session, Vote 20
secondary · model gpt-5.5 · confidence 90%

The statute defines applicable entities to include drug manufacturers, rebate aggregators, group purchasing organizations, wholesalers, distributors, affiliates, and related third parties; it also defines plan sponsor by reference to ERISA.

The enacted language ties the 100 percent pass-through duty to manufacturer and rebate-aggregator payments and to ERISA plan sponsors, matching the substance of the commitment for plan sponsors.

delivered same_term A for effort

Congress.gov bill text for H.R.7148, Consolidated Appropriations Act, 2026
secondary · model gpt-5.5 · confidence 86%

S.2199 was sponsored by Sen. Shaheen and included insulin contracting requirements barring group plans, issuers, and contracted PBM entities from receiving manufacturer rebates, reductions in price, or other remuneration for certified insulin, but Congress.gov records it only as introduced and referred to Senate Finance.

Before enactment through H.R.7148, Shaheen had taken concrete legislative action on insulin-specific PBM rebate restrictions, though that earlier bill did not pass.

partial unknown A for effort

Congress.gov bill text for S.2199, Insulin Price Reduction Act
secondary · model gpt-5.5 · confidence 84%